ClinicalTrials.gg
CompletedNCT06046729Updated Aug 21, 2026

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 2 interventional study of Eltrekibart and Placebo in Hidradenitis Suppurativa, sponsored by Eli Lilly and Company. Completed at 74 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
22nd of 139
352 · median 45
Started
2023
with 12 others
Phase 2
61 of 161
11 open now
Registered
108th of 161
by date

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 22nd largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2023, is one of 61 in phase 2, and was the 108th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

03

Conditions studied

  • Hidradenitis Suppurativa
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of HS for at least 12 months.
  • Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.
  • Have an (abscess plus inflammatory nodule) count of at least 5.
  • Agree to use topical antiseptics daily.
  • Had an inadequate response or intolerance to a 28-day course of oral antibiotics.

Exclusion criteria

Exclusion Criteria:

  • Have more than 20 draining fistulae.
  • Have had surgical treatment for HS in the last 4 weeks before randomization.
  • Have an active skin disease or condition, that could interfere with the assessment of HS.
  • Have a current or recent acute, active infection.
  • Are .
  • Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
352 participants (actual)

Study arms

  • Experimental
    Eltrekibart Dose 1

    Eltrekibart will be given subcutaneously (SC).

    Drug: Eltrekibart

  • Experimental
    Eltrekibart Dose 2

    Eltrekibart will be given SC.

    Drug: Eltrekibart

  • Experimental
    Eltrekibart Dose 3

    Eltrekibart will be given SC.

    Drug: Eltrekibart

  • Placebo comparator
    Placebo

    Placebo will be given.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3041658

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)

    Time frame: Week 16

Secondary outcomes

  1. Mean Change from Baseline in Total Number of Abscesses and Inflammatory Nodules

    Time frame: Baseline, Week 16

  2. Mean Change from Baseline in HS-related Average Skin Pain Numerical Rating Scale (NRS)

    Time frame: Baseline, Week 16

  3. Pharmacokinetics (PK): Plasma Concentrations of Eltrekibart

    Time frame: Baseline through Week 16

07

Study locations

74 sites
  • Medical Dermatology Specialists
    Phoenix, Arizona 85006, United States
  • Saguaro Dermatology Associates, LLC - Probity - PPDS
    Phoenix, Arizona 85008, United States
  • Arkansas Research Trials, LLC
    North Little Rock, Arkansas 72117, United States
  • Northwest Arkansas Clinical Trials Center
    Rogers, Arkansas 72758, United States
  • First OC Dermatology Research Inc
    Fountain Valley, California 92708, United States
  • Center For Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Dermatology Institute and Skin Care Center
    Santa Monica, California 90404, United States
  • University of Connecticut
    Farmington, Connecticut 06032, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • University of Miami
    Miami, Florida 33125, United States
  • Skin Research of South Florida
    Miami, Florida 33173-1407, United States
  • ForCare Clinical Research
    Tampa, Florida 33613-1244, United States
  • Alliance Clinical Research of Tampa
    Tampa, Florida 33615, United States
  • Olympian Clinical Research
    Tampa, Florida 33615, United States
  • Advanced Medical Research, PC
    Sandy Springs, Georgia 30328, United States
  • NorthShore Medical Group Dermatology - Skokie
    Skokie, Illinois 60077-1049, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Equity Medical - Bowling Green
    Bowling Green, Kentucky 42104, United States
  • Derm Research LLC
    Louisville, Kentucky 40217, United States
  • Care Access-Marriottsville
    Marriottsville, Maryland 21104, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Revival Research Institute - Troy
    Troy, Michigan 48084, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Skin Specialists, P.C
    Omaha, Nebraska 68144, United States
  • ActivMed Practices & Research, Inc.
    Portsmouth, New Hampshire 03801, United States
  • Darst Dermatology
    Charlotte, North Carolina 28277-8014, United States
  • Dermatology Specialists of Charlotte
    Charlotte, North Carolina 28277, United States
  • Duke University Medical Center
    Durham, North Carolina 27710-3038, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Apex Clinical Research Center
    Mayfield Heights, Ohio 44124, United States
  • DermDox Centers for Dermatology
    Camp Hill, Pennsylvania 17011, United States
  • DermDox Dermatology Centers
    Sugarloaf, Pennsylvania 18249, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Columbia Dermatology & Aesthetics
    Columbia, South Carolina 29212-8623, United States
  • International Clinical Research - Tennessee (IC Research)
    Murfreesboro, Tennessee 37130, United States
  • Advanced Research Experts
    Nashville, Tennessee 37211, United States
  • Modern Research Associates
    Dallas, Texas 75231, United States
  • North Texas Clinical Research
    Frisco, Texas 75034, United States
  • Jordan Valley Dermatology Center
    South Jordan, Utah 84095, United States
  • Dermatology Specialists of Spokane
    Spokane, Washington 99202-1332, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • East Sydney Doctors
    Darlinghurst, New South Wales 2010, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Sunshine Coast University Hospital
    Birtinya, Queensland 4575, Australia
  • Sinclair Dermatology - East Melbourne
    East Melbourne, Victoria 3002, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Fremantle Dermatology
    Fremantle, Western Australia 6160, Australia
  • Holdsworth House Medical Practice
    Sydney, 2010, Australia
  • Beacon Dermatology
    Calgary, Alberta T3E 0B2, Canada
  • Alberta Dermasurgery Centre
    Edmonton, Alberta T6G 1C3, Canada
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Brunswick Dermatology Center
    Fredericton, New Brunswick E3B 1G9, Canada
  • Simcoderm Medical & Surgical Dermatology Centre
    Barrie, Ontario L4M 7G1, Canada
  • DermEffects - Probity - PPDS
    London, Ontario N6H 5L5, Canada
  • Center de Recherche St Louis
    Québec, Quebec G1W 4R4, Canada
  • Hautklinik Erlangen
    Erlangen, Bavaria 91054, Germany
  • Hautarztpraxis Mahlow
    Blankenfelde-Mahlow, Brandenburg 15827, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt am Main, Hesse 60596, Germany
  • Universitaetsklinikum der Ruhr-Universitaet Bochum (UKRUB) - St. Josef-Hospital
    Bochum, North Rhine-Westphalia 44791, Germany
  • Universitätsklinikum Bonn
    Bonn, North Rhine-Westphalia 53127, Germany
  • Universitätsklinikum Münster - Albert Schweitzer Campus
    Münster, Westfalen 48149, Germany
  • Hautzentrum Friedrichshain - Dermatologie
    Berlin, 10247, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20251, Germany
  • Hospital of Venereal and Skin Diseases A.Syggros
    Athens, Attica 16121, Greece
  • University General Hospital of Heraklion Loc. 1
    Heraklion, Irakleío 711 10, Greece
  • Papageorgiou General Hospital of Thessaloniki
    Thessaloniki, Thessaloníki 56429, Greece
  • Cityclinic Przychodnia Lekarsko Psychologiczna Matusiak Spółka Partnerska
    Wroclaw, Lower Silesian Voivodeship 50-566, Poland
  • Wro Medica
    Wroclaw, Lower Silesian Voivodeship 51-685, Poland
  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i Administracji
    Warsaw, Masovian Voivodeship 02-507, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, Pomeranian Voivodeship 80-214, Poland
  • Klinika Badawcza Centrum Badan Klinicznych Wojciech Brzezicki
    Malbork, Pomeranian Voivodeship 82-200, Poland
  • Centrum Medyczne Pratia Katowice
    Katowice, Silesian Voivodeship 40-081, Poland
  • Dermoklinika-Centrum Medyczne s.c
    Lodz, Łódź Voivodeship 90-436, Poland
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Sep 2025, 23 months.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 23 months is above that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Sep 21, 2023
StartActual
Oct 23, 2023
Primary completionActual
Sep 30, 2025
CompletionActual
Aug 17, 2026
Results delay requested
Jul 23, 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06046729
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Oct 23, 2023
Primary completion
Sep 30, 2025
Completion
Aug 17, 2026
Last update
Aug 21, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrekibart

Start the discussion